<?xml version="1.0" encoding="UTF-8"?>
<modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
  <mods>
    <titleInfo>
      <title>High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households</title>
    </titleInfo>
    <name type="personnal">
      <namePart type="family">Fritz</namePart>
      <namePart type="given">Matthieu</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Rosolen</namePart>
      <namePart type="given">B.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Krafft</namePart>
      <namePart type="given">E.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Becquart</namePart>
      <namePart type="given">Pierre</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Elguero</namePart>
      <namePart type="given">Eric</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Vratskikh</namePart>
      <namePart type="given">O.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Denolly</namePart>
      <namePart type="given">S.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Boson</namePart>
      <namePart type="given">B.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Vanhomwegen</namePart>
      <namePart type="given">J.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Gouilh</namePart>
      <namePart type="given">M. A.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Kodjo</namePart>
      <namePart type="given">A.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Chirouze</namePart>
      <namePart type="given">C.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Rosolen</namePart>
      <namePart type="given">S. G.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Legros</namePart>
      <namePart type="given">V.</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <name type="personnal">
      <namePart type="family">Leroy</namePart>
      <namePart type="given">Eric</namePart>
      <role>
        <roleTerm type="text">auteur</roleTerm>
        <roleTerm type="code" authority="marcrelator">aut</roleTerm>
      </role>
      <affiliation>IRD</affiliation>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="local">journalArticle</genre>
    <language>
      <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <physicalDescription>
      <internetMediaType>text/pdf</internetMediaType>
      <digitalOrigin>reformatted digital</digitalOrigin>
      <reformattingQuality>access</reformattingQuality>
    </physicalDescription>
    <abstract>In a survey of household cats and dogs of laboratory-confirmed COVID-19 patients, we found a high seroprevalence of SARS-CoV-2 antibodies, ranging from 21% to 53%, depending on the positivity criteria chosen. Seropositivity was significantly greater among pets from COVID-19+ households compared to those with owners of unknown status. Our results highlight the potential role of pets in the spread of the epidemic.</abstract>
    <targetAudience authority="marctarget">specialized</targetAudience>
    <subject>
      <topic>SARS-CoV-2</topic>
      <topic>COVID-19</topic>
      <topic>Pets</topic>
      <topic>Seroprevalence</topic>
      <topic>One health</topic>
      <topic>Luminex</topic>
      <topic>Neutralization assay</topic>
    </subject>
    <subject authority="local">
      <geographic>FRANCE</geographic>
      <geographic>FRANCHE COMTE</geographic>
      <geographic>RHONE ALPES</geographic>
    </subject>
    <classification authority="local">052</classification>
    <classification authority="local">080</classification>
    <classification authority="local">020</classification>
    <relatedItem type="host">
      <titleInfo>
        <title>One Health</title>
      </titleInfo>
      <part>
        <detail type="volume">
          <number>11</number>
        </detail>
        <extent unit="pages">
          <list>100192 [5 ]</list>
        </extent>
      </part>
      <originInfo>
        <dateIssued>2020</dateIssued>
      </originInfo>
    </relatedItem>
    <identifier type="uri">https://www.documentation.ird.fr/hor/fdi:010080578</identifier>
    <identifier type="doi">10.1016/j.onehlt.2020.100192</identifier>
    <location>
      <shelfLocator>[F B010080578]</shelfLocator>
      <url usage="primary display" access="object in context">https://www.documentation.ird.fr/hor/fdi:010080578</url>
      <url access="row object">https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers21-01/010080578.pdf</url>
    </location>
    <recordInfo>
      <recordContentSource>IRD - Base Horizon / Pleins textes</recordContentSource>
      <recordCreationDate encoding="w3cdtf">2021-02-08</recordCreationDate>
      <recordChangeDate encoding="w3cdtf">2025-02-24</recordChangeDate>
      <recordIdentifier>fdi:010080578</recordIdentifier>
      <languageOfCataloging>
        <languageTerm authority="iso639-2b">fre</languageTerm>
      </languageOfCataloging>
    </recordInfo>
  </mods>
</modsCollection>
